Bio-Techne (TECH) news

Avtech Q3 EBITDA SEK 4.3 million

Avtech reported an Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of SEK 4.3 million for the third quarter of 2026. This metric reflects the company’s operating performance by excluding the impact of financing costs, tax policies, and non-cash accounting charges such as…

Cleo Diagnostics Ltd - Cleo commences analytical validation ahead of FDA submission

Cleo Diagnostics Limited (ASX: COV) has entered the analytical validation (AV) phase for its ovarian cancer detection blood test, marking a significant step toward its planned U.S. Food and Drug Administration (FDA) submission. This follows the completion of commercial assay development and key…

Cleo Diagnostics - Receives first batch of commercially manufactured test kits

Cleo Diagnostics Limited (ASX: COV) has received its first batch of commercially manufactured test kits from Bio-Techne, marking a key step in its regulatory pathway toward FDA submission. This development follows the commencement of kit manufacturing in April 2026 and supports the company’s…

German Federal Cartel Office approves the takeover of Bio-Techne by Merck KGaA (Darmstadt)

The German Federal Cartel Office has approved Merck KGaA’s (Darmstadt) proposed acquisition of Bio-Techne Corporation, a U.S.-based global provider of life science tools and analytical technologies. The approval marks a key regulatory milestone for the transaction, which is valued at approximately…

Bio-Techne 4Q net sales $321.2M, est. $314.6M